GRI Bio Cash and Cash Equivalents Reach $8.2M
As of December 31, 2025, the Company had cash and cash equivalents of approximately $8.2M. Following the close of the quarter, the Company raised an additional $6.5M in gross proceeds through the use of its At The Market offering. Based on the Company's current operating plan, GRI Bio believes that its existing cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements into the first quarter of 2027. Net loss was $12M for the year ended December 31, 2025. "In 2025, we prioritized disciplined clinical execution and balance sheet strength, delivering compelling clinical data from our lead IPF program which underscores the therapeutic differentiation of GRI-0621," commented Marc Hertz, CEO. "Entering 2026 with a strong cash position, we are focused on advancing GRI-0621 in IPF, progressing GRI-0803 toward the clinic and executing our clinical strategy with capital discipline to drive long-term value creation."
